Latest Europe News

Deep Yellow has pushed back its targeted fourth-quarter Final Investment Decision for the Tumas uranium project, citing unfavourable equity market conditions. The delay comes as engineering reaches 85%, construction works begin and cash falls to A$144.7 million.

Raiden Resources has resubmitted the environmental documentation needed to support a permit re-issue for its Crixás gold tailings project in Brazil. The company says approval would allow it to begin evaluating drilling, metallurgy and a potential near-term production pathway, although the project still has no JORC-compliant resource or reserve.

OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.

Almasar Minerals ended its first post-listing quarter with A$10.24 million in cash and a pipeline of geophysical surveys and auger drilling across its Saudi Arabian licences. The company has yet to report new exploration results, leaving execution and target quality as the next tests for the newly listed explorer.

Foresta has secured acceptance of a Japanese patent for its rosin and terpene extraction technology while moving the Kawerau pine chemicals project through front-end design. But with $2.47 million in cash and estimated funding for 2.65 quarters, the next development stage will bring a financing question into sharper focus.

Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.

Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.

Everest Metals’ Mt Edon project has been selected as Australia’s representative site in a five-year German-funded exploration program and accepted into the European Union’s Raw Materials Mechanism. The recognition may improve access to technical expertise, strategic partners and potential financing, although no funding, offtake or development commitment was announced.

Evion Group has secured mining permits for its flagship Maniry graphite project in Madagascar and signed its first binding supply commitment, while its Nevada fluorspar exploration and Indian downstream operations also advanced. The company ended September with A$5.755 million in cash, but major development milestones still depend on funding, approvals and final agreements.

AML3D has carried $16.8 million of orders into FY27, with its US defence expansion driving a sales pipeline above $80 million. Customer receipts rose 19% in the September quarter, while the company retained $24.42 million in cash to fund capacity expansion.

Lovisa delivered another year of strong reported growth, with revenue rising 17.6% to A$938.8 million as its store network passed 1,100 locations. But comparable store sales grew just 2.0%, leaving management’s expansion engine carrying more of the load while executive incentive hurdles went unmet.

Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.